NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecul... NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was incorporated in 2005 and is headquartered in Calabasas, California. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.1295 | 2.79094827586 | 4.64 | 4.94 | 4.24 | 42829 | 4.47691529 | CS |
| 4 | -0.8505 | -15.1334519573 | 5.62 | 5.9 | 4.16 | 46158 | 4.88160786 | CS |
| 12 | -3.1105 | -39.4733502538 | 7.88 | 8.15 | 3.87 | 69147 | 5.24993873 | CS |
| 26 | -4.6505 | -49.3683651805 | 9.42 | 11.3765 | 3.87 | 62847 | 7.12674816 | CS |
| 52 | -1.8305 | -27.7348484848 | 6.6 | 12.99 | 3.2 | 104504 | 6.74186304 | CS |
| 156 | -7.2805 | -60.4190871369 | 12.05 | 21 | 3.2 | 98756 | 6.82892577 | CS |
| 260 | -7.2805 | -60.4190871369 | 12.05 | 21 | 3.2 | 98756 | 6.82892577 | CS |
Money wake
1年前
Money wake
1年前
Money wake
1年前
Money wake
1年前
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。